MICHAEL LEWIS to Heterografts
This is a "connection" page, showing publications MICHAEL LEWIS has written about Heterografts.
Connection Strength
0.791
-
The Power and Promise of Patient-Derived Xenografts of Human Breast Cancer. Cold Spring Harb Perspect Med. 2024 04 01; 14(4).
Score: 0.220
-
Surgical Procedure for Implantation of Human Tumor Tissue into the Epithelium-Free Mammary Fat Pad of Immunocompromised Mice to Generate Patient-Derived Xenografts (PDX). Methods Mol Biol. 2022; 2471:195-207.
Score: 0.188
-
Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment. Nat Commun. 2021 08 24; 12(1):5086.
Score: 0.183
-
A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology. Nat Cancer. 2022 02; 3(2):232-250.
Score: 0.047
-
EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nat Commun. 2017 06 12; 8:15773.
Score: 0.034
-
Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev. 2016 12; 35(4):547-573.
Score: 0.033
-
Patient-derived xenograft models of breast cancer and their predictive power. Breast Cancer Res. 2015 Feb 10; 17:17.
Score: 0.029
-
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Res. 2015 Jan 09; 17:3.
Score: 0.029
-
Wnt-responsive cancer stem cells are located close to distorted blood vessels and not in hypoxic regions in a p53-null mouse model of human breast cancer. Stem Cells Transl Med. 2014 Jul; 3(7):857-66.
Score: 0.028